300
Views
49
CrossRef citations to date
0
Altmetric
Drug Evaluations

Talaporfin sodium

, , , &
Pages 133-140 | Published online: 10 Dec 2009

Bibliography

  • DeRosa MC, Crutchley RJ. Photosensitized singlet oxygen and its applications. Coord Chem Rev 2002;233:351-71
  • Matheson IB, Etheridge RD, Kratowich NR, Lee J. The quenching of singlet oxygen by amino acids and proteins. Photochem Photobiol 1975;21:165-71
  • Nilsson R, Merkel PB, Kearns DR. Unambiguous evidence for the participation of singlet oxygen (1) in photodynamic oxidation of amino acids. Photochem Photobiol 1972;16:117-24
  • Pazos MC, Nader HB. Effect of photodynamic therapy on the extracellular matrix and associated components. Braz J Med Biol Res 2007;40:1025-35
  • Wright A, Bubb WA, Hawkins CL, Davies MJ. Singlet oxygen-mediated protein oxidation: evidence for the formation of reactive side chain peroxides on tyrosine residues. Photochem Photobiol 2002;76:35-46
  • Zhuang S, Ouedraogo GD, Kochevar IE. Downregulation of epidermal growth factor receptor signaling by singlet oxygen through activation of caspase-3 and protein phosphatases. Oncogene 2003;22:4413-24
  • Chen W, Yewdell JW, Levine RL, Bennink JR. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J Exp Med 1999;189:1757-64
  • Bromley E, Owczarczak B, Keltner L, Characterization of an anti-tumor immune response after light-activated drug therapy using talaporfin sodium in a spontaneously metastasizing mammary tumor model. J Clin Oncol 2009;27(Suppl): abstract 3052
  • McMahon KS, Wieman TJ, Moore PH, Fingar VH. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response. Cancer Res 1994;54:5374-9
  • Shibuya H, Aizawa K, Okunaka T, Acute microvascular response to photodynamic therapy with mono-L- aspartyl chlorin e6 and a diode laser: observation under modified operation microscope. J Tokyo Med Univ 1999;57:136-44
  • Xu H, Liang Y, Krouse M, Ablation of liver tumors with novel light activated drug-device technology (Litx): targeting feeding vessels may permit killing of larger tumor volumes. ASCO GI Cancers Symposium, 27 – 29 January 2005, Hollywood, Florida: ASCO; 2005. p. 143 (poster abstract 21)
  • Preise D, Oren R, Glinert I, Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity. Cancer Immunol Immunother 2009;58:71-84
  • Harvey EH, Webber J, Kessel D, Fromm D. Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398. Am J Surg 2005;189:302-5
  • Bellnier DA, Dougherty TJ. A preliminary pharmacokinetic study of intravenous Photofrin in patients. J Clin Laser Med Surg 1996;14:311-14
  • Allen RP, Kessel D, Tharratt RS, Volz W. Photodynamic therapy of superficial malignancies with NPe6 in man. In: Spinelli P, Dal Fante M, Marchesini R, editors, Photodynamic therapy and biomedical lasers. Amsterdam: Excerpta Medica; 1992. p. 441-5
  • Taber SW, Fingar VH, Coots CT, Wieman TJ. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study. Clin Cancer Res 1998;4:2741-6
  • Volz W, Allen R. Cutaneous phototoxicity of NPe6 in man. In: Spinelli P, Dal Fonte M, Marchesini R, editors, Photodynamic therapy and biomedical lasers. Amsterdam: Excerpta Medica; 1992. p. 446-8
  • Kato H, Furukawa K, Sato M, Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer 2003;42:103-11
  • Keltner L, Chen JC, Wang S, Rakić ML. A phase 2a study of light-activated talaporfin sodium in patients with primary or recurrent glioblastoma multiforme. J Clin Oncol 2009;27(Suppl): abstract e13026
  • Lustig RA, Vogl TJ, Fromm D, A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors. Cancer 2003;98:1767-71
  • Wang S, Keltner L, Winship J, Lee W. A Phase 1/2 safety and efficacy study of intratumoral light-activated drug therapy using talaporfin sodium in patients with inoperable hepatocellular carcinoma. J Clin Oncol 2009;27(Suppl): abstract e15684
  • Kujundzic M, Vogl TJ, Stimac D, A Phase II safety and effect on time to tumor progression study of intratumoral light infusion technology using talaporfin sodium in patients with metastatic colorectal cancer. J Surg Oncol 2007;96:518-24
  • Finlay E, Casarett D. Making difficult discussions easier: using prognosis to facilitate transitions to hospice. CA Cancer J Clin 2009;59:250-63
  • Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
  • Grizzi F, Chiriva-Internati M. Cancer: looking for simplicity and finding complexity. Cancer Cell Int 2006;6:4
  • Hennessy BT, Gonzalez-Angulo AM, Carey MS, Mills GB. A systems approach to analysis of molecular complexity in breast cancer. Clin Cancer Res 2009;15:417-19
  • Teschendorff AE, Journee M, Absil PA, Elucidating the altered transcriptional programs in breast cancer using independent component analysis. PLoS Comput Biol 2007;3:e161
  • Bredel M, Scholtens DM, Harsh GR, A network model of a cooperative genetic landscape in brain tumors. JAMA 2009;302:261-75
  • Tonon G. From oncogene to network addiction: the new frontier of cancer genomics and therapeutics. Future Oncol 2008;4:569-77

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.